Home
Immediapress
Pr Newswire
Comunicato stampa - contenuto promozionale
Responsabilità editoriale PrNewswire
SHANGHAI, June 24, 2026 /PRNewswire/ -- Jiahui International Cancer Center (JICC) welcomes the approval of Satri-cel (CT041, Kaileimei®), the world's first CAR-T cell therapy approved for the treatment of a solid tumor, marking a historic milestone in cancer care and opening new
Home
Immediapress
Pr Newswire
Comunicato stampa - contenuto promozionale
Responsabilità editoriale PrNewswire

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

China Approves World’s First CAR-T Therapy for Solid Tumors

CARsgen makes history as China approves world's first CAR-T therapy for solid tumors

Araris Biotech AG e Taiho Oncology annunciano la somministrazione del trattamento al primo paziente in uno studio clinico di fase 1 su ARC-02, un nuovo ADC per il trattamento del linfoma non-Hodgkin

Cancro al seno metastatico, ok in Ue a nuovo trattamento in prima linea - Il Quotidiano del Sud

Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T

CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors

CARsgen’s Kailimei wins clearance for late-line CLDN18.2-positive, HER2-negative gastric cancer, marking a milestone for cell…

The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products…

Lo indica una sperimentazione condotta in Cina (ANSA)

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented…

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026